- Home
- AGI vs BLCO Comparison
AGI vs BLCO Comparison
Compare AGI & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGI
- BLCO
- Stock Information
- Founded
- AGI 2003
- BLCO 1853
- Country
- AGI Canada
- BLCO Canada
- Employees
- AGI N/A
- BLCO N/A
- Industry
- AGI Precious Metals
- BLCO Ophthalmic Goods
- Sector
- AGI Basic Materials
- BLCO Health Care
- Exchange
- AGI Nasdaq
- BLCO Nasdaq
- Market Cap
- AGI 7.6B
- BLCO 7.0B
- IPO Year
- AGI 1999
- BLCO 2022
- Fundamental
- Price
- AGI $18.32
- BLCO $18.02
- Analyst Decision
- AGI Strong Buy
- BLCO Buy
- Analyst Count
- AGI 5
- BLCO 12
- Target Price
- AGI $22.25
- BLCO $20.91
- AVG Volume (30 Days)
- AGI 2.3M
- BLCO 524.8K
- Earning Date
- AGI 02-19-2025
- BLCO 10-30-2024
- Dividend Yield
- AGI 0.55%
- BLCO N/A
- EPS Growth
- AGI 18.31
- BLCO N/A
- EPS
- AGI 0.60
- BLCO N/A
- Revenue
- AGI $1,225,700,000.00
- BLCO $4,684,000,000.00
- Revenue This Year
- AGI $33.98
- BLCO $17.39
- Revenue Next Year
- AGI $20.42
- BLCO $6.18
- P/E Ratio
- AGI $31.54
- BLCO N/A
- Revenue Growth
- AGI 22.50
- BLCO 18.01
- 52 Week Low
- AGI $11.24
- BLCO $13.16
- 52 Week High
- AGI $21.45
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- AGI 42.32
- BLCO 36.81
- Support Level
- AGI $17.95
- BLCO $17.71
- Resistance Level
- AGI $20.45
- BLCO $18.99
- Average True Range (ATR)
- AGI 0.60
- BLCO 0.52
- MACD
- AGI -0.10
- BLCO -0.17
- Stochastic Oscillator
- AGI 14.80
- BLCO 10.17
About AGI Alamos Gold Inc.
Alamos Gold Inc acquires, explores, and produces gold and other precious metals, and operates in two principal geographic areas: Canada and Mexico. The company has three operating mines in North America: Young-Davidson and Island Gold mines operate in Canada and the Mulatos and in Sonora, Mexico. The company generates maximum revenue from the Mulatos mines.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.